Market Capitalization: Genmab US (GMAB)

Risks for Genmab A/S (GMAB) are linked to a dependence on royalties from a single product and fierce competition within the biotech sector, with a market capitalization of 33.37. This daily price chart reflects the dynamics of a company developing precision medicines. Its high status as an innovative antibody developer is supported by a cohesive team of R&D specialists and the active recruitment of clinical trial experts worldwide.

Genmab - GMAB Market Value (period 07/04/2022 - 11/11/2026)

Genmab Corp - analytical breakdowns and key metrics (GMAB)

- market price and analyst price targets:

Price Chart Genmab|GMAB - Consensus Target

- company stock exchange capitalization indicators:

Market Capitalization Genmab Corp|GMAB - Enterprise Value

- issuer book value statistics:

Book Value per Share Genmab|GMAB - Company Book Value|Market Value to Book Value Ratio genmab.com|GMAB - Company Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

GMAB - Company Net Income|Projected Future Earnings Genmab A/S|GMAB - Market Cap to Net Income Ratio|Projected Price to Earnings Genmab US|GMAB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Genmab Corp|GMAB - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Genmab|GMAB - Earnings per share for the last four quarters|Quarterly EPS earnings growth genmab.com|GMAB - Earnings growth in current year|Net earnings per share growth forecast for next year Genmab A/S

Analysis of all company metrics:GMAB (Genmab)

Market capitalization is the product of the current share price and the total number of outstanding securities, capturing the final market consensus on the business value at the close of the trading day. The current capitalization trend for Genmab A/S reflects investor confidence in the resilience of its oncology ecosystem, where steady demand for life-saving therapies offsets FDA regulatory risks.

Competitor analysis